Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 266.96M | 304.34M | 308.13M | 301.87M | 257.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 266.96M | 304.34M | 308.13M | 301.87M | 257.24M |
| Cost of Revenue | 117.55M | 168.26M | 180.22M | 176.70M | 158.99M |
| Gross Profit | 149.41M | 136.08M | 127.91M | 125.17M | 98.25M |
| SG&A Expenses | 150.44M | 163.44M | 174.32M | 184.29M | 183.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 361.33M | 426.57M | 453.38M | 461.15M | 448.74M |
| Operating Income | -94.37M | -122.23M | -145.25M | -159.28M | -191.50M |
| Income Before Tax | 28.51M | -450.00K | -29.72M | -59.67M | -238.27M |
| Income Tax Expenses | -- | 0.00 | -380.00K | -380.00K | -380.00K |
| Earnings from Continuing Operations | 28.51 | -0.45 | -29.34 | -59.29 | -237.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.51M | -450.00K | -29.34M | -59.29M | -237.89M |
| EBIT | -94.37M | -122.23M | -145.25M | -159.28M | -191.50M |
| EBITDA | -89.09M | -116.92M | -140.59M | -154.93M | -187.71M |
| EPS Basic | 0.27 | -0.01 | -0.32 | -0.70 | -2.57 |
| Normalized Basic EPS | -1.48 | -0.70 | -0.88 | -1.18 | -1.53 |
| EPS Diluted | 0.15 | -0.10 | -0.41 | -0.79 | -2.58 |
| Normalized Diluted EPS | -1.45 | -0.68 | -0.86 | -1.16 | -1.53 |
| Average Basic Shares Outstanding | 458.20M | 454.27M | 436.80M | 409.25M | 375.77M |
| Average Diluted Shares Outstanding | 470.98M | 467.05M | 449.58M | 422.03M | 375.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
